CYP3A4,5 oxidise AFB1 to AFXBO

Stable Identifier
R-HSA-213175
Type
Reaction [transition]
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

Aflatoxins are produced by the fungal molds Aspergillus flavus and Aspergillus parasiticus. Dietary contamination accounts for adverse health problems including liver cancer therby classifying aflatoxins as Group 1 carcinogens in humans. The B1 form of aflatoxin (AFB1) is especially carcinogenic in a number of species including humans.
AFB1 requires microsomal oxidation to produce epoxides which are the cause of their toxic and carcinogenic effects. In humans, both CYP3A4 and CYP3A5 are able to produce epoxide stereoisomers of AFB1, the most potent being aflatoxin B1 exo-8,9-oxide (AFXBO) (Gallagher et al. 1996).

Literature References
PubMed ID Title Journal Year
15454734 Increased levels of aflatoxin-albumin adducts are associated with CYP3A5 polymorphisms in The Gambia, West Africa

Wojnowski, L, Turner, PC, Pedersen, B, Hustert, E, Brockmöller, J, Mendy, M, Whittle, HC, Kirk, G, Wild, CP

Pharmacogenetics 2004
8975785 The kinetics of aflatoxin B1 oxidation by human cDNA-expressed and human liver microsomal cytochromes P450 1A2 and 3A4

Gallagher, EP, Kunze, KL, Stapleton, PL, Eaton, DL

Toxicol. Appl. Pharmacol. 1996
Participants
Participant Of
hasEvent
Catalyst Activity
Catalyst Activity
Title
monooxygenase activity of Cytochrome P450 (CYP3A5 based) [endoplasmic reticulum membrane]
Physical Entity
Activity
Orthologous Events
Authored
Reviewed
Created